Klas G Wiman

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5800205/publications.pdf

Version: 2024-02-01

		31976	32842
115	10,570	53	100
papers	citations	h-index	g-index

124	124	124	10209
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nature Medicine, 2002, 8, 282-288.	30.7	981
2	Targeting mutant p53 for efficient cancer therapy. Nature Reviews Cancer, 2018, 18, 89-102.	28.4	655
3	PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain. Cancer Cell, 2009, 15, 376-388.	16.8	508
4	Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nature Medicine, 1997, 3, 632-638.	30.7	348
5	Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer. Journal of Clinical Oncology, 2012, 30, 3633-3639.	1.6	346
6	What is the restriction point?. Current Opinion in Cell Biology, 1995, 7, 835-842.	5.4	320
7	Shaping Genetic Alterations in Human Cancer: The p53 Mutation Paradigm. Cancer Cell, 2007, 12, 303-312.	16.8	316
8	Activation of a translocated human c-myc gene by an enhancer in the immunoglobulin heavy-chain locus. Nature, 1984, 307, 334-340.	27.8	272
9	Wrap53, a Natural p53 Antisense Transcript Required for p53 Induction upon DNA Damage. Molecular Cell, 2009, 33, 462-471.	9.7	242
10	Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells. Oncogene, 2000, 19, 5123-5133.	5.9	235
11	Inhibiting the system xCâ^'/glutathione axis selectively targets cancers with mutant-p53 accumulation. Nature Communications, 2017, 8, 14844.	12.8	229
12	The p53 tumor suppressor: A master regulator of diverse cellular processes and therapeutic target in cancer. Biochemical and Biophysical Research Communications, 2010, 396, 85-89.	2.1	225
13	PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis. Oncogene, 2005, 24, 3484-3491.	5.9	216
14	Reactivation of Mutant p53 and Induction of Apoptosis in Human Tumor Cells by Maleimide Analogs. Journal of Biological Chemistry, 2005, 280, 30384-30391.	3.4	207
15	p14^{ARF} Deletion and Methylation in Genetic Pathways to Glioblastomas. Brain Pathology, 2001, 11, 159-168.	4.1	197
16	APR-246 reactivates mutant p53 by targeting cysteines 124 and 277. Cell Death and Disease, 2018, 9, 439.	6.3	182
17	Characterization of the p53-rescue drug CP-31398 in vitro and in living cells. Oncogene, 2002, 21, 2119-2129.	5.9	173
18	p53 binds single-stranded DNA ends through the C-terminal domain and internal DNA segments via the middle domain. Nucleic Acids Research, 1995, 23, 362-369.	14.5	163

#	Article	IF	Citations
19	Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53. Genes and Development, 2014, 28, 58-70.	5.9	156
20	Mutant p53 reactivation by small molecules makes its way to the clinic. FEBS Letters, 2014, 588, 2622-2627.	2.8	154
21	Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database. Carcinogenesis, 2002, 23, 2011-2018.	2.8	152
22	APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells. Cell Death and Disease, 2015, 6, e1794-e1794.	6.3	151
23	hTERT antagonizes p53-induced apoptosis independently of telomerase activity. Oncogene, 2005, 24, 1320-1327.	5.9	150
24	Reactivation of Mutant p53 through Interaction of a C-Terminal Peptide with the Core Domain. Molecular and Cellular Biology, 1999, 19, 3395-3402.	2.3	145
25	Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 13303-13307.	7.1	145
26	APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase. Cell Death and Disease, 2013, 4, e881-e881.	6.3	142
27	The retinoblastoma gene: role in cell cycle control and cell differentiation. FASEB Journal, 1993, 7, 841-845.	0.5	129
28	WRAP53 Is Essential for Cajal Body Formation and for Targeting the Survival of Motor Neuron Complex to Cajal Bodies. PLoS Biology, 2010, 8, e1000521.	5.6	116
29	p53: A Cell Cycle Regulator Activated by DNA Damage. Advances in Cancer Research, 1995, 66, 143-180.	5.0	107
30	A novel high-through-put assay for screening of pro-apoptotic drugs. Investigational New Drugs, 2002, 20, 253-259.	2.6	103
31	Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy. Frontiers in Oncology, 2016, 6, 21.	2.8	99
32	Role of genetic and epigenetic changes in Burkitt lymphoma. Seminars in Cancer Biology, 2002, 12, 381-387.	9.6	98
33	p53 targets identified by protein expression profiling. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 5401-5406.	7.1	95
34	Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis. Oncogene, 2010, 29, 1329-1338.	5.9	95
35	Mutant p53 targeting by the low molecular weight compound STIMAâ€1. Molecular Oncology, 2008, 2, 70-80.	4.6	91
36	p16/INK4a and p15/INK4b Gene Methylation and Absence of p16/INK4a mRNA and Protein Expression in Burkitt's Lymphoma. Blood, 1998, 91, 1680-1687.	1.4	90

#	Article	IF	Citations
37	p14ARF homozygous deletion or MDM2 overexpression in Burkitt lymphoma lines carrying wild type p53. Oncogene, 2001, 20, 2171-2177.	5.9	88
38	APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma. Gut, 2015, 64, 1506-1516.	12.1	84
39	p53-Induced Apoptosis as a Safeguard against Cancer. Biochemical and Biophysical Research Communications, 1999, 265, 1-6.	2.1	80
40	The p53 target Wig-1 regulates p53 mRNA stability through an AU-rich element. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 15756-15761.	7.1	80
41	Immunolocalization of Human p14ARF to the Granular Component of the Interphase Nucleolus. Experimental Cell Research, 2000, 256, 400-410.	2.6	79
42	Myc and E2F1 induce p53 through p14ARF-independent mechanisms in human fibroblasts. Oncogene, 2003, 22, 4993-5005.	5.9	78
43	Genetic landscape of hepatitis B virusâ€“associated diffuse large B-cell lymphoma. Blood, 2018, 131, 2670-2681.	1.4	77
44	Human cancer-associated fibroblasts enhance glutathione levels and antagonize drug-induced prostate cancer cell death. Cell Death and Disease, 2017, 8, e2848-e2848.	6.3	76
45	p53 as a hub in cellular redox regulation and therapeutic target in cancer. Journal of Molecular Cell Biology, 2019, 11, 330-341.	3.3	71
46	Impaired epithelial differentiation of induced pluripotent stem cells from ectodermal dysplasia-related patients is rescued by the small compound APR-246/PRIMA-1 ^{MET}. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 2152-2156.	7.1	69
47	Wig-1, a new p53-induced gene encoding a zinc finger protein. Oncogene, 1997, 15, 2699-2704.	5.9	66
48	Reactivation of mutant p53: a new strategy for cancer therapy. Seminars in Cancer Biology, 1998, 8, 369-378.	9.6	64
49	30 years and a long way into p53 research. Lancet Oncology, The, 2009, 10, 913-919.	10.7	63
50	Frequent expression of Bcl-2 in renal-cell carcinomas carrying wild-type p53. , 1996, 66, 322-325.		62
51	The single-stranded DNA end binding site of p53 coincides with the C- terminal regulatory region. Nucleic Acids Research, 1996, 24, 3560-3567.	14.5	61
52	Regulation of tumor suppressor p53 at the RNA level. Journal of Molecular Medicine, 2010, 88, 645-652.	3.9	61
53	Human wig-1, a p53 target gene that encodes a growth inhibitory zinc finger protein. Oncogene, 2001, 20, 5466-5474.	5.9	60
54	Effects of the TP53 p.R249S mutant on proliferation and clonogenic properties in human hepatocellular carcinoma cell lines: interaction with hepatitis B virus X protein. Carcinogenesis, 2010, 31, 1475-1482.	2.8	55

#	Article	IF	Citations
55	Interleukin-6 derived from cancer-associated fibroblasts attenuates the p53 response to doxorubicin in prostate cancer cells. Cell Death Discovery, 2020, 6, 42.	4.7	55
56	PRIMA-1MET/APR-246 targets mutant forms of p53 family members p63 and p73. Oncogene, 2010, 29, 6442-6451.	5.9	54
57	Inhibition of the glutaredoxin and thioredoxin systems and ribonucleotide reductase by mutant p53-targeting compound APR-246. Scientific Reports, 2018, 8, 12671.	3.3	53
58	Novel cancer therapy by reactivation of the p53 apoptosis pathway. Annals of Medicine, 2003, 35, 458-465.	3.8	52
59	Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer. Journal of Ovarian Research, 2016, 9, 27.	3.0	51
60	The p53-induced mouse zinc finger protein wig-1 binds double-stranded RNA with high affinity. Nucleic Acids Research, 2002, 30, 1991-1996.	14.5	48
61	Mutant p53 rescue and modulation of p53 redox state. Cell Cycle, 2009, 8, 2509-2517.	2.6	43
62	Regulation of p53R2 and its role as potential target for cancer therapy. Cancer Letters, 2009, 276, 1-7.	7.2	40
63	PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53. Cellular Oncology, 2008, 30, 411-8.	1.9	40
64	Characterization of human buccal epithelial cells transfected with the simian virus 40 T-antigen gene. Carcinogenesis, 1995, 16, 2515-2521.	2.8	37
65	APR-246/PRIMA-1MET rescues epidermal differentiation in skin keratinocytes derived from EEC syndrome patients with p63 mutations. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 2157-2162.	7.1	37
66	PRIMA-1met radiosensitizes prostate cancer cells independent of their MTp53-status. Radiotherapy and Oncology, 2008, 86, 407-411.	0.6	36
67	Restoration of Wildâ€Type p53 Function in Human Tumors: Strategies for Efficient Cancer Therapy. Advances in Cancer Research, 2007, 97, 321-338.	5.0	29
68	p53: Emergency Brake and Target for Cancer Therapy. Experimental Cell Research, 1997, 237, 14-18.	2.6	28
69	In vitro and in vivo cytotoxic effects of PRIMA-1 on hepatocellular carcinoma cells expressing mutant p53ser249. Carcinogenesis, 2008, 29, 1428-1434.	2.8	28
70	A thiolâ€bound drug reservoir enhances APRâ€246â€induced mutant p53 tumor cell death. EMBO Molecular Medicine, 2021, 13, e10852.	6.9	28
71	Identification and functional characterization of new missense SNPs in the coding region of the TP53 gene. Cell Death and Differentiation, 2021, 28, 1477-1492.	11.2	26
72	Is conversion of solid into more anoxic ascites tumors associated with p53 inactivation?. Oncogene, 1998, 17, 2333-2337.	5.9	25

#	Article	IF	Citations
73	The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer Cells. Translational Oncology, 2018, 11, 1343-1349.	3.7	25
74	An old acquaintance resurfaces in human mesothelioma. Nature Medicine, 1997, 3, 839-840.	30.7	23
75	Synergistic Rescue of Nonsense Mutant Tumor Suppressor p53 by Combination Treatment with Aminoglycosides and Mdm2 Inhibitors. Frontiers in Oncology, 2017, 7, 323.	2.8	22
76	Progressive B-cell chronic lymphocytic leukaemia frequently exhibits aberrantp53 expression. International Journal of Cancer, 1994, 58, 474-479.	5.1	21
77	The p53 target protein Wigâ€1 binds hnRNP A2/B1 and RNA Helicase A via RNA. FEBS Letters, 2008, 582, 2173-2177.	2.8	21
78	Role of Thiol Reactivity for Targeting Mutant p53. Cell Chemical Biology, 2018, 25, 1219-1230.e3.	5.2	20
79	p53 contributes to T cell homeostasis through the induction of pro-apoptotic SAP. Cell Cycle, 2012, 11, 4563-4569.	2.6	19
80	Wild-type p53-induced apoptosis in a Burkitt lymphoma cell line is inhibited by interferon gamma. , 1996, 67, 106-112.		18
81	p53 splice acceptor site mutation and increased HsRAD51 protein expression in Bloom's syndrome GM1492 fibroblasts. Gene, 2000, 246, 247-254.	2.2	18
82	The p53-induced Wig-1 protein binds double-stranded RNAs with structural characteristics of siRNAs and miRNAs. FEBS Letters, 2006, 580, 4401-4408.	2.8	17
83	New p53-based anti-cancer therapeutic strategies. Medical Oncology and Tumor Pharmacotherapy, 1998, 15, 222-228.	1.1	16
84	A melanoma-predisposing germline CDKN2A mutation with functional significance for both p16 and p14ARF. Cancer Letters, 2002, 180, 211-221.	7.2	15
85	Identification of functional p53-binding motifs in the mouse wig-1 promoter. FEBS Letters, 2002, 524, 69-72.	2.8	14
86	Extract from Asteraceae Brachylaena ramiflora induces apoptosis preferentially in mutant p53-expressing human tumor cells. Carcinogenesis, 2010, 31, 1045-1053.	2.8	14
87	Genome-wide identification of Wig-1 mRNA targets by RIP-Seq analysis. Oncotarget, 2016, 7, 1895-1911.	1.8	14
88	cMyc-p53 feedback mechanism regulates the dynamics of T lymphocytes in the immune response. Cell Cycle, 2016, 15, 1267-1275.	2.6	13
89	Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells. Cell Death and Disease, 2021, 12, 709.	6.3	11
90	Position-dependent nuclear accumulation of the retinoblastoma (RB) protein during in vitro myogenesis. Journal of Cellular Physiology, 1993, 155, 313-322.	4.1	10

#	Article	IF	Citations
91	Evolutionary history of the p53 family DNA-binding domain: insights from an Alvinella pompejana homolog. Cell Death and Disease, 2022, 13, 214.	6.3	10
92	The p53-induced Wig-1 zinc finger protein is highly conserved from fish to man. International Journal of Oncology, 2004, 24, 1559-64.	3.3	9
93	Functional characterization of novel germline TP53 variants in Swedish families. Clinical Genetics, 2019, 96, 216-225.	2.0	7
94	p16/INK4a and p15/INK4b Gene Methylation and Absence of p16/INK4a mRNA and Protein Expression in Burkitt's Lymphoma. Blood, 1998, 91, 1680-1687.	1.4	7
95	PRIMA-1MET induces nucleolar translocation of Epstein-Barr virus-encoded EBNA-5 protein. Molecular Cancer, 2009, 8, 23.	19.2	6
96	RB-reconstituted human retinoblastoma cells formRB-positive intraocular and intracerebral but not subcutaneous tumors in scid mice. International Journal of Cancer, 1995, 61, 683-691.	5.1	4
97	Low p14ARF expression inde novoacute myeloid leukemia with normal karyotype is associated with poor survival. Leukemia and Lymphoma, 2009, 50, 1512-1518.	1.3	4
98	p53 as a target for improved cancer therapy. Expert Opinion on Therapeutic Targets, 1999, 3, 347-353.	1.0	3
99	A splice donor site mutation results in the insertion of five extra amino acids into P53 from SEWA mouse sarcoma cells. Gene, 1995, 162, 231-234.	2.2	2
100	Functional Rescue of Mutant p53 as a Strategy to Combat Cancer. , 2002, , 397-415.		2
101	Expression of the p53 Target Wig-1 Is Associated with HPV Status and Patient Survival in Cervical Carcinoma. PLoS ONE, 2014, 9, e111125.	2.5	2
102	Abstract 1849: High nuclear expression of the p53 target Wig-1 is associated with poor prognosis in cervical carcinoma. , 2014, , .		1
103	Preclinical Efficacy and Toxicology Studies of APR-246, a Novel Anticancer Compound Currently In Clinical Trials for Refractory Hematological Malignancies and Prostate Cancer. Blood, 2010, 116, 1806-1806.	1.4	1
104	Mutant p53 Reactivation as a Novel Strategy for Cancer Therapy. , 2007, , 399-419.		1
105	Abstract CT204: Preliminary results from PiSARRO, a phase Ib/II study of APR-246, a mutant p53 reactivating small molecule, in combination with standard chemotherapy in platinum-sensitive ovarian cancer. , 2015, , .		1
106	Wig-1, a p53-Induced Zinc Finger Protein that Binds Double Stranded RNA. , 2005, , 76-79.		0
107	Cancer Therapy by Reactivation of the p53 Apoptosis Pathway. , 0, , 891-912.		0
108	Targeting Mutant p53 for Improved Cancer Therapy. , 2013, , 257-273.		0

#	Article	IF	Citations
109	Abstract 3448: Strong synergistic effects with cisplatin and APR-246, a novel compound reactivating mutant p53, in ovarian cancer cell lines and primary cells from patients.. , 2013, , .		0
110	Abstract 1801: APR-246, a clinical-stage mutant p53-reactivating compound, resensitizes ovarian cancer cells to platinum compounds and doxorubicin. , 2014, , .		0
111	Abstract 110: The role of the p53 target Wig-1 in senescence and cancer. , 2015, , .		0
112	Abstract 1639: Strong synergy with APR-246 and DNA-damaging drugs in primary ovarian cancer cells. , 2015, , .		0
113	Abstract 4357: Harnessing system xCT- to target mutant p53 cancer cells. , 2016, , .		0
114	Impact of combined MRP1 inhibition and mutant p53-targeting compound APR-246.. Journal of Clinical Oncology, 2019, 37, e14712-e14712.	1.6	0
115	Mutant p53 Reactivation as a Novel Strategy for Cancer Therapy. , 2007, , 399-419.		0